BIO REFERENCE LABORATORIES INC
NT 10-K, 1999-01-29
MEDICAL LABORATORIES
Previous: GRANITE STATE BANKSHARES INC, SC 13G, 1999-01-29
Next: HANCOCK JOHN STRATEGIC SERIES, N-30D, 1999-01-29



                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C.  20549

                           NOTIFICATION OF LATE FILING

                                   FORM 12b-25

SEC File Number  0-15266                 Cusip Number  09057G 60 2          
               ----------------------                -----------------------

                                   [Check One]
     |X| Form 10-K |_| Form 20-F |_| Form 11-K |_| Form 10-Q |_| Form N-SAR

                  For the Period Ended:  October 31, 1998    

                  [   ] Transition Report on Form 10-K

                  [   ] Transition Report on Form 20-F

                  [   ] Transition Report on Form 11-K

                  [   ] Transition Report on Form 10-Q

                  [   ] Transition Report on Form N-SAR

                  For the Transition Period Ended            

             Read Instructions [on back page] Before Preparing Form.
                              Please Print or Type

Nothing  in this form shall be  constructed  to imply  that the  Commission  has
verified any information contained herein

If the notification  relates to a portion of the filing checked above,  identify
the Item[s] to which the notification relates:


PART I - REGISTRANT INFORMATION
Full Name of Registrant:   BIO-REFERENCE LABORATORIES, INC.
Former Name if Applicable:
Address of Principal Executive Office [Street and Number]:
    481 EDWARD H . ROSS DRIVE
City, State and Zip Code: 
     ELMWOOD PARK, NEW JERSEY  07407

PART II - RULES 12b-25[b] and [c]
If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25[b], the following should
be completed.
                           [Check box if appropriate]

      [a] The reasons  described in  reasonable  detail in Part III of this form
          could not be eliminated without unreasonable effort or expenses;

[X]   [b] The subject annual report,  semi-annual report,  transition report
          on Form 10-K,  Form 2-F, Form 11- K, Form N-SAR,  or portion thereof,
          will be filed on or before the  fifteenth  calendar day  following the
          prescribed  due date;  or the subject  quarterly  report or transition
          report on Form 10-Q, or portion thereof will be filed on or before the
          fifth calendar day following the prescribed due date; and

      [c] The accountant's statement or other exhibit required by Rule 12b-25[c]
          has been attached if applicable.


<PAGE>



PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q
or N-SAR, or the transition report or portion thereof, could not be filed within
the  prescribed  time  period.  The Company is  attempting  to  consolidate  its
Medilabs  division  with  Bio-Reference's   headquarters  and  updating  various
computer  systems  for the  year  2000  issues  and as a result  the  accounting
department is delayed in assembling its Form 10-K package.

PART IV - OTHER INFORMATION
    [1]  Name and telephone number of person to contact in regard to
         this notification

                 Sam Singer                        201             791-2600   
                   [Name]                      [Area Code]      [Telephone No.]

    [2] Have all other  periodic  reports  required under Section 13 or 15[d] of
        the  Securities and Exchange Act of 1934 or Section 30 of the Investment
        Company Act of 1940 during the  preceding 12 months [or for such shorter
        period  that the  registrant  was  required to file such  reports]  been
        filed? If answer is no, identify report[s].[ X ] Yes [ ] No


    [3] Is it anticipated  that any significant  change in results of operations
        from the corresponding period for the last fiscal year will be reflected
        by the  earnings  statements  to be included  in the  subject  report or
        portion thereof? [ X ] Yes [ ] No

        If so, attach an explanation of the anticipated change, both narratively
        and  quantitatively,  and,  if  appropriate,  state  the  reasons  why a
        reasonable estimate of the results cannot be made.

        The Company  anticipates net income of approximately  $800,000 resulting
        from  income  from   operations  of   approximately   $1.3  million,   a
        non-recurring  gain of  approximately  $300,000  and other  expenses  of
        approximately $800,000.

                          BIO-REFERENCE LABORATORIES, INC.                 
                  [Name of Registrant as Specified in Charter]

has caused this  notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date:      January 29, 1999                    By: /s/ Sam Singer          
     ----------------------------------            ------------------------
                                                   Sam Singer, Vice President

INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly  authorized  representative.  The name and title of the person
signing  the form  shall  be typed or  printed  beneath  the  signature.  If the
statement is signed on behalf of the registrant by an authorized  representative
[other than an executive officer], evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

                                    ATTENTION
           Intentional misstatements or omissions of fact constitute
                Federal Criminal Violation  [See 18 U.S.C. 1001]

                              GENERAL INSTRUCTIONS

1.  This form is  required  by Rule  12b-25 [17 CFR  240.12b-25]  of the General
    Rules and Regulations under the Securities Exchange Act of 1934.

2.  One signed  original and four  conformed  copies of this form and amendments
    thereto  must be  completed  and  filed  with the  Securities  and  Exchange
    Commission,  Washington,  D.C.  20549,  in  accordance  with Rule 0-3 of the
    General Rules and Regulations under the Act. The information contained in or
    filed  with  the form  will be made a matter  of the  public  record  in the
    Commission files.

3.  A manually  signed copy of the form and  amendments  thereto  shall be filed
    with each national  securities  exchange on which any class of securities of
    the registrant is registered.

4   Amendments to the notifications  must also be filed on form 12b-25, but need
    not restate information that has been correctly furnished. The form shall be
    clearly identified as an amendment notification.

5.  Electronic  Filers - This form shall not be used by electronic filers unable
    to timely file a report solely due to electronic difficulties. Filers unable
    to submit a report within the time period  prescribed due to difficulties in
    electronic  filing  should  comply  with  either  Rule  201 or  Rule  202 of
    Regulation  S-T or apply for an  adjustment  in filing date pursuant to Rule
    13(b) of Regulation S-T.


<PAGE>


                                                                 EXHIBIT A

                              MOORE STEPHENS, P.C.
                          CERTIFIED PUBLIC ACCOUNTANTS
                         340 NORTH AVENUE EAST, SUITE 6
                         CRANFORD, NEW JERSEY 07016-2461






                                          January 28, 1999



Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Gentlemen:

       We are  retained  by  Bio-Reference  Laboratories,  Inc.  as  independent
certified  public  accountants to report on the financial  statements at October
31, 1998 and for the fiscal year then ended. We have  endeavored,  with the full
cooperation  of the Company,  to obtain the  necessary  information  to meet the
filing  requirements  for Form 10-K, both as to form and timeliness.  Due to the
extensive  period of time,  and the  related  delay in  developing  data for the
financial statements,  we will not have sufficient time to finalize our audit by
January 29, 1999 which is the  required  filing  date for the  Company's  annual
report, without unreasonable effort and expense.

                                          Very truly yours,




                                          MOORE STEPHENS, P.C.
<PAGE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission